<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medbio</journal-id><journal-title-group><journal-title xml:lang="ru">Медико-биологические проблемы жизнедеятельности</journal-title><trans-title-group xml:lang="en"><trans-title>Medical and Biological Problems of Life Activity</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2088</issn><publisher><publisher-name>Республиканский научно-практический центр радиационной медицины и экологии человека</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.58708/2074-2088.2025-3(35)-89-95</article-id><article-id custom-type="elpub" pub-id-type="custom">medbio-457</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Риски клинической манифестации сахарного диабета 2 типа у населения трудоспособного возраста</article-title><trans-title-group xml:lang="en"><trans-title>Risks of clinical manifestation of diabetes mellitus type 2 in the working-age population</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рожко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rozhko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Гомель</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рожко</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rozhko</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Гомель</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савастеева</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Savasteeva</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Гомель</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГУ «РНПЦ радиационной медицины и экологии человека»</institution></aff><aff xml:lang="en"><institution>ГУ «РНПЦ радиационной медицины и экологии человека»</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2025</year></pub-date><volume>0</volume><issue>3</issue><fpage>89</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рожко А.В., Рожко В.А., Савастеева И.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Рожко А.В., Рожко В.А., Савастеева И.Г.</copyright-holder><copyright-holder xml:lang="en">Rozhko A.V., Rozhko V.A., Savasteeva I.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medbio.ejournal.by/jour/article/view/457">https://medbio.ejournal.by/jour/article/view/457</self-uri><abstract><p>В ходе эпидемиологического исследования установлено, что количество случаев реализации СД 2 типа у мужчин и женщин нарастает с увеличением биологического возраста, с более ранней (на 7–10 лет) реализацией заболевания у мужчин. Формирование пика СД 2 типа у мужчин зарегистрировано в возрастном периоде 35–39 лет, у женщин – 45–49 лет.</p><p>Среди пациентов в возрасте 34–39 лет, не имеющих верифицированного диагноза СД 2 типа на момент скрининга, у 8,1% зарегистрировано смещение липидограммы в сторону атерогенеза. Повышение уровня случайной гликемии выше целевых значений зарегистрировано у 0,4% обследованных; уровня гликированного гемоглобина выше целевых показателей – у 1,8% и требовало постановки диагнозов «преддиабет» или «СД 2 типа». Данные биохимические изменения указывают на бессимптомное течение СД 2 типа. Это говорит о необходимости контроля гликированного гемоглобина и липидограммы. А пациентов, имеющих смещение липидограммы в сторону атерогенеза, необходимо расматривать как группу риска формирования СД 2 типа.</p></abstract><trans-abstract xml:lang="en"><p>An epidemiological study found that the incidence of type 2 diabetes melitus in men and women increases with increasing biological age, with an earlier onset (by 7–10 years) in men. The peak of DM type 2 in men was observed between the ages of 35 and 39, and in women, between the ages of 45 and 49. Among patients aged 34-39 who did not have a verified diagnosis of DM type 2 at the time of screening, 8.1% had a lipid profile shift toward atherogenesis. Increases in random glycemia above target values were observed in 0,4% of those examined, and glycated hemoglobin levels above target values occurred in 1,8%, demanding establishment of a diagnosis of prediabetes or DM type 2. These biochemical changes indicate an asymptomatic course of DM type 2 and necessity of monitoring of glycated hemoglobin and lipid profile. Patients with a lipid profile shifting towards atherogenesis should be considered as a risk group for the development of DM type 2.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2 типа</kwd><kwd>липидограмма</kwd><kwd>гликированный гемоглобин</kwd><kwd>относительный риск</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>prediabetes</kwd><kwd>risk factors</kwd><kwd>relative risk</kwd><kwd>primary incidence</kwd><kwd>working age</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) // European Heart Journal. – 1 January 2020 / – V. 41, Issue 1. – P.111–188.</mixed-citation><mixed-citation xml:lang="en">2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) // European Heart Journal. – 1 January 2020 / – V. 41, Issue 1. – P.111–188.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia. Report of a WHO/IDF consultation. Доступно по: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/ (June 14 2019).</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia. Report of a WHO/IDF consultation. Доступно по: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/ (June 14 2019).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association ADA. Standards of medical care in diabetes-2020. Diabetes Care 2020.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association ADA. Standards of medical care in diabetes-2020. Diabetes Care 2020.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD // European Heart Journal. – 2019. – V.00. P.1-69.</mixed-citation><mixed-citation xml:lang="en">2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD // European Heart Journal. – 2019. – V.00. P.1-69.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care // Obes Facts. – 2019. V.12. P.40–66.</mixed-citation><mixed-citation xml:lang="en">European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care // Obes Facts. – 2019. V.12. P.40–66.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
